Processing

Please wait...

Settings

Settings

Goto Application

1. WO1996018292 - CONTROLLING DONOR BLOOD CHARACTERISTICS

Publication Number WO/1996/018292
Publication Date 20.06.1996
International Application No. PCT/US1995/010705
International Filing Date 22.08.1995
IPC
A61K 35/14 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
CPC
A61K 35/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
Applicants
  • BAXTER INTERNATIONAL INC. [US]/[US]
Inventors
  • GRODE, Gerald, A.
  • STEWART, Mary, A.
Agents
  • BARRETT, Joseph, B.
Priority Data
08/357,81216.12.1994US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) CONTROLLING DONOR BLOOD CHARACTERISTICS
(FR) CONTROLE DES CARACTERISTIQUES DU SANG D'UN DONNEUR
Abstract
(EN)
A new citrate-based anticoagulant for donor whole blood provides good platelet yield and cell morphology at a significantly reduced risk of donor paresthesia during apheresis procedures. The primary citrate anticoagulant compositions include a citric acid to total citrate ration greater than about 30 %. The anticoagulants are mixed with whole blood to provide an anticoagulated blood mixture which contains a citric acid concentration of greater than about 5.0 mM, a total citrate concentration of less than about 20 mM, and an initial blood pH of less than about 6.75. The platelet rich products including PRP and PC prepared from blood collected in accordance with the invention exhibit better platelet yields and better platelet morphology on storage.
(FR)
Nouvel anti-coagulant à base de citrate pour le sang entier d'un donneur permet d'obtenir une bonne production des plaquettes ainsi qu'une bonne morphologie des cellules avec un risque considérablement réduit de parasthésie du donneur lors de procédures d'aphérèse. Les principales compositions anti-coagulantes à base de citrate ont un rapport acide citrique/quantité totale de citrate supérieur à environ 30 %. Les anti-coagulants sont mélangés à du sang entier afin d'obtenir un mélange de sang anti-coagulé dont la concentration en acide citrique est supérieure à environ 5,0 mM, une concentration totale de citrate inférieure à environ 20 mM, et un pH de sang initial inférieur à environ 6,75. Le produit riche en plaquettes y compris PRP et PC préparé à partir de sang récupéré selon l'invention présente de meilleurs taux de plaquettes et une meilleure morphologie des plaquettes pendant le stockage.
Also published as
Latest bibliographic data on file with the International Bureau